Pacific Biosciences of California Inc.

Ark Invest is continuing to pour money into one of its favorite tech stocks.

Ark Invest also trimmed its top holding by nearly $10 million.

Ark Invest just picked up more than 200,000 shares of this company.

Wood clearly believes in this biotech company.

Recent announcements are likely better news for 10x Genomics and Twist Bioscience than the DNA sequencing pioneer.

There's only one way to succeed in lab hardware. Despite a promising platform, Bionano Genomics remains a long way from sustainable success.

The DNA sequencing giant generated over 10% of its diluted earnings per share in 2021 from a tax holiday.

A complicated merger situation for Illumina just got messier.

A handful of biotech stocks were catapulted higher by short squeezes. Whether they will recover their losses is an open question.

The genomics company PacBio isn't making much progress in the most important source of revenue.

Shares of the genetic testing company have more than doubled in less than a week. It likely isn't durable.

DNA-sequencing leader Illumina swung to a loss in Q2 2022. Contributions from Grail didn't help.

The formerly high-flying growth stock is stalling against macroeconomic headwinds. How quickly can the business get back on track?

This lab-hardware business is growing, cashed up, and close to profitability.

On Wednesday, Ark snapped up shares of Twilio, Roblox, Coinbase and JD.com. It sold Twitter and Palantir Technologies.

Invitae says a $1.15 billion investment from a Softbank-led group will support the medical-genetics company's growth opportunities.

Pacific Biosciences says Softbank's $900 million investment 'validates our leadership position in the long-read DNA sequencing market.'

Jim Cramer says young investors may have unorthodox investing ideas, but their strategies are working. Here's what they're buying.

U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve’s Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.

Let's review the charts of PACB again.

The stock bottomed in June/July and have worked higher.

The Tuttle Capital Short Innovation exchange-traded fund has been outperforming just about everything lately -- here's how and what to consider before you jump aboard.

Plus, Ford and Rivian, and SoFi Technologies' national bank charter.

Let's check on breadth, the Russell 2000, new highs and more.

A recent trio of acquisition deals indicates the doldrums in the sector may be over.

Let's check out the charts and technical indicators.

This candlestick pattern is very successful in catching significant tops.

The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.

Here is why it hasn’t been limited to one direction.

The change applies to website and mobile-app payments.

Not all crypto experts are bullish on Trump's latest venture.

Here's what the legendary billionaire says could be next for the stock market.